CBER’s New Director “Marks” A New Era For Biologics Regulation

Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.

More from Archive

More from Pink Sheet